This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n7http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/genbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/uniprotkb/
n24http://linked.opendata.cz/resource/AHFS/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/wikipedia/
n17http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/pharmgkb/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n27http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/kegg-drug/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/drugbank/
n4http://www.rxlist.com/cgi/generic/
n18http://linked.opendata.cz/resource/drugbank/patent/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00026/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
n16http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n25http://www.drugs.com/cdi/
n21http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00026
rdf:type
n5:Drug
n5:description
Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. FDA approved on November 14, 2001.
n5:dosage
n26:271B4039-363D-11E5-9242-09173F13E4C5 n26:271B403A-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352 # Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J; Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI): Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008 Mar;67(3):281-2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17947302 # FDA label
n5:group
approved
n5:halfLife
Healthy subjects = 4 - 6 hours; NOMID patients = 5.7 hours (range of 3.1 - 28.2 hours).
n5:indication
For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
owl:sameAs
n20:DB00026 n27:DB00026
dcterms:title
Anakinra
adms:identifier
n7:M55646 n9:DB00026 n10:66658-234-28 n11:P18510 n12:D02934 n14:PA10799 n15:Anakinra
n5:mechanismOfAction
Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.
n5:packager
n22:271B4036-363D-11E5-9242-09173F13E4C5 n22:271B4035-363D-11E5-9242-09173F13E4C5
n5:patent
n18:2141953 n18:1341322
n5:synonym
IL-1ra Interleukin-1 receptor antagonist protein precursor IRAP IL-1RN IL1 inhibitor ICIL-1RA
n5:toxicity
Most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain when anakinra is used in RA patients. In NOMID patients, the most common AEs during the first 6 months of treatment (incidence >10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis.
n23:hasAHFSCode
n24:92-00-00
n16:hasConcept
n17:M0494869
foaf:page
n4:anakinra.htm n25:anakinra.html
n5:Molecular-Formula
n21:271B403E-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n21:271B403D-363D-11E5-9242-09173F13E4C5
n23:hasATCCode
n28:L04AC03
n5:absorption
When a 70 mg subcutaneous bolus injection is given to healthy subjects, the absolute bioavailability is 95%. Accumulation does not occur following daily subcutaneous doses. Tmax, SubQ, 1-2 mg/kg, healthy subjects = 3-7 hours; Cmax, SubQ, 3 mg/kg once daily, NOMID patients = 3628 ng/mL.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
143090-92-0
n5:category
n5:clearance
Clearance is variable and increases with increasing creatinine clearance and body weight. However, gender and age were not significant factors.
n5:containedIn
n8:271B4037-363D-11E5-9242-09173F13E4C5 n8:271B4038-363D-11E5-9242-09173F13E4C5
n5:Hydrophobicity
n21:271B403B-363D-11E5-9242-09173F13E4C5
n5:Isoelectric-Point
n21:271B403C-363D-11E5-9242-09173F13E4C5